27.3 C
New York
Thursday, June 11, 2026

Tag: Meta

Smart Women Invest: Why Amazon Stock Could Boost Your Portfolio This July

Hey lovely ladies, let’s dive into the world of Amazon and see if it’s a good time to grab some of those shiny stocks...

June 2025 Quarterly Exploration Results

82km of drilling and $9M invested in resource development and exploration in Q4, FY25 PERTH, Western Australia, July 23, 2025 /CNW/ - Westgold Resources Limited...

Agoda launches first-ever brand campaign in Singapore with AI-powered commercials

SINGAPORE, July 22, 2025 /PRNewswire/ -- Digital travel platform Agoda launched its first-ever brand campaign in Singapore, centred around an AI-powered commercials that spotlights...

EISAI TO PRESENT FOUR-YEAR EFFICACY AND SAFETY DATA ON CONTINUOUS TREATMENT WITH LECANEMAB AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025

Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab long-term data, an immunoassay for measuring amyloid-β protofibrils in cerebrospinal fluid,...

Bridging Innovation: The Role of ACM and SIGGRAPH in Advancing Computer Graphics

ACM President Yannis Ioannidis and SIGGRAPH 2025 Conference Chair Ginger Alford Reflect on the Evolving Partnership Driving AI-Powered Breakthroughs in Graphics and Interactive Technology. NEW...

Natural Appetite Suppressant: Why More Are Choosing PhenQ Over Weight Loss Injections for Safer Weight Management Results in 2025

New York City, NY, July 21, 2025 (GLOBE NEWSWIRE) -- PhenQ is leading the 2025 weight loss revolution with a science-backed natural appetite suppressant—no needles, no harsh side effects, just sustainable, healthy weight control

DV INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that DoubleVerify Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against DoubleVerify Holdings, Inc. (“DoubleVerify” or “the Company”) (NYSE: DV) and certain of its officers.

DV DEADLINE NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages DoubleVerify Holdings, Inc. Investors to Secure Counsel Before Important July 21 Deadline in Securities Class Action...

NEW YORK, July 19, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of DoubleVerify Holdings, Inc. (NYSE: DV) between November 10, 2023 and February 27, 2025, both dates inclusive (the “Class Period”), of the important July 21, 2025 lead plaintiff deadline.

Purpose Investments Inc. Announces July 2025 Distributions

TORONTO, July 18, 2025 (GLOBE NEWSWIRE) -- Purpose Investments Inc. (“Purpose”) is pleased to announce distributions for the month of July 2025 for its open-end exchange traded funds and closed-end funds (“the Funds”).

Purpose Investments Inc. annonce les distributions de juillet 2025

TORONTO, 18 juill. 2025 (GLOBE NEWSWIRE) -- Purpose Investments Inc. (« Purpose ») a le plaisir d’annoncer des distributions pour le mois de de juillet 2025 pour ses fonds négociés en bourse à capital variable et ses fonds à capital fixe (les « Fonds »).

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

Nature Medicine Published Phase 1 Results of Innovent Biologics’ Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality...

AI Wizards Leave Google, Brew New Gizmo

A new AI agent, Asimov, is trying to revolutionize how software is developed, but let’s keep our feet on the ground here. Built by...

- A word from our sponsors -

spot_img
HomeTagsMeta